An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: Lessons to be drawn

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1519-1530

  Tjan Heijnen, V C G ^a   Wagener, D J T ^a   Postmus, P E ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Dose; Dose intensity; Review; Small cell lung cancer

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CLASSIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; LUNG SMALL CELL CANCER; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL; TREATMENT OUTCOME;

EID: 0036810184     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf249     Document Type: Review

References (35)

1. Tjan-Heijnen VCG, Postmus PE, Wagener DJT. Dose-intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer. Anticancer Drugs 1997; 8: 549-564.
2. Pignon JP, Arriagada R, Ihde D et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618-1628.
3. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999; 341: 476-484.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 68: 43-61.
5. MacNeil M, Eisenhauer EA. High-dose chemotherapy: is it standard management for any common solid tumor? Ann Oncol 1999; 10: 1145-1161.
6. Fizazi K, Zelek L. Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000; 11: 133-149.
7. Maurer LH, Tulloh M, Weiss RB et al. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy, effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 1980; 45: 30-39.
8. Ettinger DS, Finkelstein DM, Abeloff MD et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8: 230-240.
9. Cullen M, Morgan D, Gregory W et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized controlled trial. Cancer Chemother Pharmacol 1986; 17: 157-160.
10. Bleehen NM, Fayers PM, Girling DJ et al. A randomized trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989; 59: 584-590.
11. Lebeau B, Chastang Cl, Allard P et al. Six vs. twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J 1992; 5: 286-290.
12. Giaccone G, Dalesio O, McVie GJ et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11: 1230-1240.
13. Spiro SG, Souhami RL, Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59: 578-583.
14. Bleehen NM, Girling DJ, Machin D et al. A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Br J Cancer 1993; 68: 1150-1156.
15. Figueredo AT, Hryniuk WM, Strautmanis I et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small cell lung cancer. J Clin Oncol 1985; 3: 54-64.
16. Johnson DH, Einhorn, LH, Birch R et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5: 1731-1738.
17. Ihde DC, Mulshine JL, Kramer BS et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
18. Arriagada R, Le Chevalier T, Pignon JP et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848-1852.
19. Humblet Y, Symann M, Bosly A et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell lung carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864-1873.
20. Woll PJ, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-659.
21. Fukuoka M, Masuda N, Negoro S et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75: 306-309.
22. Steward WP, von Pawel J, Gatzemeier U et al. Effects of granulocyte macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 1998; 16: 642-650.
23. Thatcher N, Girling DJ, Hopwood P et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony stimulating factor support: results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 2000; 18: 395-404.
24. Miles DW, Fogarty O, Ash CM et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12: 77-82.
25. James LE, Gower NH, Rudd RM et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996; 73: 1563-1568.
26. Pujol JL, Douillard JY, Rivière A et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multicenter randomized phase III study. J Clin Oncol 1997; 15: 2082-2089.
27. Tjan-Heijnen VCG, Ardizzoni A, Postmus PE et al. Dose-intensification of cyclophosphamide, doxorubicin and etoposide (CDE)-chemotherapy does not improve survival in small cell lung cancer (SCLC): final results of a randomized phase III EORTC study. Proc Am Soc Clin Oncol 2001; 20: 346 (Abstr 1379).
28. Cohen MH, Creaven PJ, Fossieck BE et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349-354.
29. Postmus PE, Berendsen HH, Van Zandwijk N et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1997; 23: 1409-1411.
30. Chute JP, Chen T, Feigal E et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794-1801.
31. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
32. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-324.
33. Gatzemeier U, Kleisbauer JP, Drings P et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer. Am J Clin Oncol 2000; 23: 393-400.
34. Hamm J, Schiller JH, Cuffie C et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994; 12: 2667-2676.
35. Bunn PA, Crowley J, Kelly K et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-1641.